Dibenzyl diselenide, beyond its roles in catalysis and as an antioxidant, is emerging as a significant player in the fight against infectious diseases, demonstrating broad-spectrum antiviral and antimicrobial activities.

In the realm of virology, research indicates that dibenzyl diselenide and related organoselenium compounds possess the capability to inhibit the replication of various viruses. Studies have explored their potential against pathogens responsible for herpes simplex, hepatitis C, HIV, and even SARS-CoV-2. A key mechanism proposed for this antiviral action is virucidal activity – the compound directly destroys virus particles, which can be advantageous in preventing the development of drug resistance. Molecular docking studies suggest that dibenzyl diselenide might interact with essential viral enzymes, further inhibiting viral proliferation.

Equally impressive are its antimicrobial properties. Dibenzyl diselenide has shown effectiveness against a range of bacteria and fungi, notably inhibiting the formation of biofilms. Biofilms are problematic as they shield microorganisms from antibiotics and host immune responses, leading to persistent infections. The ability of dibenzyl diselenide to disrupt biofilm formation in pathogenic microbes like Staphylococcus aureus and Candida albicans at low concentrations is a significant finding. This action, combined with its direct antimicrobial effects, suggests a dual approach to combating microbial infections.

The exploration of dibenzyl diselenide antiviral and dibenzyl diselenide antimicrobial activities is a rapidly advancing field. Researchers are investigating the precise mechanisms by which it exerts these effects, considering its impact on cellular redox balance and its potential to interfere with microbial metabolic processes. As the global threat of infectious diseases continues, compounds like dibenzyl diselenide, with their broad-spectrum efficacy, represent a vital area of research for developing new and effective treatments.